RCKT Stock Analysis: Rocket Pharmaceuticals | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 281m USD | 12M Return: -44.3% | US77313F1066 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 5.88M
Qual. Beats: -1
Qual. Beats: -1
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Rocket Pharmaceuticals (RCKT) is a late-stage biotechnology company headquartered in Cranbury, New Jersey, that develops genetic therapies for rare and devastating diseases. The company operates a dual-platform gene therapy model, leveraging in vivo adeno-associated viral (AAV) programs and ex vivo lentiviral (LV) programs to address multiple underserved indications. Its AAV pipeline includes RP-A501 for Danon disease (Phase 2), RP-A601 for PKP2-associated arrhythmogenic cardiomyopathy (Phase 1), and a preclinical BAG3 dilated cardiomyopathy program. The LV pipeline covers RP-L201 for Leukocyte Adhesion Deficiency-I, RP-L102 for Fanconi Anemia, and RP-L301 for Pyruvate Kinase Deficiency.
Founded in 1999 and listed on NASDAQ since February 2015, Rocket relies on a partnership-driven R&D model, holding license agreements with academic and research institutions including the Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, UCL Business PLC, the Regents of the University of California, and Temple University. As a clinical-stage biotech with no commercial product revenue, the companys funding typically comes from capital markets and collaborations, and its rare disease focus positions it to potentially benefit from regulatory pathways such as orphan drug designation.
- Phase 2 Danon disease gene therapy data due
- Cash runway tightens as net loss widens
- FDA sets BLA pathway for LAD-I gene therapy
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.40 > 0.02 and ΔFCF/TA 8.69 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.40 > 3% & CFO -170.3m > Net Income -17.2m |
| Net Debt (-258.9m) to EBITDA (5.80m): -44.61 < 3 |
| Current Ratio: 9.24 > 1.5 & < 3 |
| Outstanding Shares: last quarter (114.5m) vs 12m ago 3.15% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 2.18%; Δ -2.18% > 0%) |
| Interest Coverage Ratio: -0.83 > 6 (EBIT TTM -3.90m / Interest Expense TTM 4.73m) |
| A: 0.61 (Total Current Assets 289.6m - Total Current Liabilities 31.3m) / Total Assets 423.1m |
| B: -3.23 (Retained Earnings -1.37b / Total Assets 423.1m) |
| C: -0.01 (EBIT TTM -3.90m / Avg Total Assets 422.0m) |
| D: 6.80 (Book Value of Equity 368.8m / Total Liabilities 54.3m) |
| Altman-Z'' = 0.56 = B |
As of October 16, 2026, the stock is trading at USD 2.36 with a total of 1,878,198 shares traded. Over the past week, the price has changed by -10.27%, over one month by -30.79%, over three months by -35.34% and over the past year by -44.34%.
Current recommended Stop Loss: 2.10 (which is 11% or 1.4 ATR below the current price).
Rocket Pharmaceuticals has received a consensus analysts rating of 3.86. Therefore, it is recommended to buy RCKT.
- StrongBuy: 6
- Buy: 1
- Hold: 6
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 8.6 | 263.6% |
P/B = 0.8974
Revenue TTM = 0.0 USD
EBIT TTM = -3.90m USD
EBITDA TTM = 5.80m USD
Long Term Debt = 21.8m USD (estimated: total debt 24.8m - short term 2.98m)
Short Term Debt = 2.98m USD (from shortTermDebt, last quarter)
Debt = 24.8m USD (from shortLongTermDebtTotal, last quarter) (leases 24.8m already included)
Net Debt = -258.9m USD (calculated: Debt 24.8m - CCE 283.7m)
Enterprise Value = 22.1m USD (281.0m + Debt 24.8m - CCE 283.7m)
Interest Coverage Ratio = -0.83 (Ebit TTM -3.90m / Interest Expense TTM 4.73m)
EV/FCF = -0.13x (Enterprise Value 22.1m / FCF TTM -170.4m)
FCF Yield = -772.0% (FCF TTM -170.4m / Enterprise Value 22.1m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 11.0m) / Revenue TTM)
Tobins Q-Ratio = 0.05 (Enterprise Value 22.1m / Total Assets 423.1m)
Interest Expense / Debt = 19.07% (Interest Expense 4.73m / Debt 24.8m)
Taxrate = 6.54% (8.62m / 131.8m)
NOPAT = -3.65m (EBIT -3.90m * (1 - 6.54%)) [loss with tax shield]
Current Ratio = 9.24 (Total Current Assets 289.6m / Total Current Liabilities 31.3m)
Debt / Equity = 0.07 (Debt 24.8m / totalStockholderEquity, last quarter 368.8m)
Debt / EBITDA = -44.61 (Net Debt -258.9m / EBITDA 5.80m)
Debt / FCF = 1.52 (negative FCF - burning cash) (Net Debt -258.9m / FCF TTM -170.4m)
Total Stockholder Equity = 299.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -4.09% (Net Income -17.2m / Total Assets 423.1m)
RoE = -5.76% (Net Income TTM -17.2m / Total Stockholder Equity 299.4m)
RoCE = -1.21% (EBIT -3.90m / Capital Employed (Equity 299.4m + L.T.Debt 21.8m))
RoIC = -0.92% (negative operating profit) (NOPAT -3.65m / Invested Capital 394.8m)
WACC = 11.39% (E(281.0m)/V(305.8m) * Re(10.82%) + D(24.8m)/V(305.8m) * Rd(19.07%) * (1-Tc(0.07)))
Discount Rate = 10.82% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 91.65 | Cagr: 9.40%
[DCF] Fair Price = unknown (Cash Flow -170.4m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -4.0 | # QB: -1
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: -4.0 | # QB: -1
EPS current Quarter (2026-09-30): EPS=-0.41 | Chg30d=+0.00% | Revisions=+17% | Analysts=5
EPS current Year (2026-12-31): EPS=-0.11 | Chg30d=+0.00% | Revisions=+25% | GrowthEPS=+94.6% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-1.30 | Chg30d=+0.00% | Revisions=+0% | GrowthEPS=-1111.2% | GrowthRev=+915.6%
[Analyst] Revisions Ratio: +22% (up=4, down=2)